Your browser doesn't support javascript.
Analysis of Outcomes in COVID-19 Patients With Varying Degrees of Hyperlipasemia.
Benias, Petros C; Inamdar, Sumant; Wee, Diana; Liu, Yan; Buscaglia, Jonathan M; Satapathy, Sanjaya K; Trindade, Arvind J.
  • Benias PC; From the Division of Gastroenterology, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, New York, NY.
  • Inamdar S; Division of Gastroenterology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR.
  • Wee D; Department of Medicine, Long Island Jewish Medical Center, Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, New Hyde Park.
  • Liu Y; Feinstein Institutes for Medical Research, Northwell Health, Manhasset.
  • Buscaglia JM; Division of Gastroenterology & Hepatology, Renaissance School of Medicine at Stony Brook University, Stony Brook.
Pancreas ; 50(9): 1310-1313, 2021 10 01.
Article in English | MEDLINE | ID: covidwho-1621703
ABSTRACT

OBJECTIVES:

Coronavirus disease 2019 (COVID-19) patients may have varying degrees of hyperlipasemia. The aim was to compare outcomes among different levels of hyperlipasemia in patients with COVID-19.

METHODS:

This is a retrospective study examining outcomes among hospitalized COVID-19 patients with a lipase <3× upper limit of normal (ULN), asymptomatic hyperlipasemia (>3× ULN), secondary pancreatitis (typical respiratory COVID-19 symptoms and found to have pancreatitis), and primary pancreatitis (presenting with pancreatitis).

RESULTS:

Of 11,883 patients admitted with COVID-19, 1560 patients were included 1155 patients had normal serum lipase (control group), 270 had elevated lipase <3× ULN, 46 patients had asymptomatic hyperlipasemia with lipase >3× ULN, 57 patients had secondary pancreatitis, and 32 patients had primary pancreatitis. On adjusted multivariate analysis, the elevated lipase <3× ULN and asymptomatic hyperlipasemia groups had worse outcomes with higher mortality (odds ratio [OR], 1.6 [95% confidence interval [CI], 1.2-2.2) and 1.1 [95% CI, 0.5-2.3], respectively), higher need for mechanical ventilation (OR, 2.8 [95% CI, 1.2-2.1] and 2.8 [95% CI, 1.5-5.2], respectively), and longer length of stay (OR, 1.5 [95% CI, 1.1-2.0] and 3.16 [95% CI, 1.5-6.5], respectively).

CONCLUSIONS:

Patients with COVID-19 with elevated lipase <3× ULN and asymptomatic hyperlipasemia have generally worse outcomes than those with pancreatitis.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pancreatitis / COVID-19 / Lipase Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: Pancreas Journal subject: Gastroenterology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pancreatitis / COVID-19 / Lipase Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: Pancreas Journal subject: Gastroenterology Year: 2021 Document Type: Article